GlassScriptPhysician profile
Andrew L Walker
NPI 1518229772
$3,355.67
in general payments reported to CMS, 2019-2025
49 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $201 · 2022: $22.53 · 2023: $518 · 2024: $1,065 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $352.17 | 2020-2025 | Erleada, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $293.44 | 2020-2025 | Enhertu, Lynparza, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $212.40 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $202.98 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $179.94 | 2019-2025 | |
| Incyte Corporation | $179.53 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Abbvie INC. | $152.10 | 2024-2025 | |
| Tersera Therapeutics LLC | $143.94 | 2023-2025 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $142.28 | 2019-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $131.71 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Glaxosmithkline, LLC. | $122.33 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $111.03 | 2019-2025 | |
| Daiichi Sankyo INC. | $96.93 | 2019-2025 | Injectafer, Datroway |
| Amgen INC. | $85.55 | 2019-2020 | |
| Taiho Oncology, INC. | $85.24 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.